Medical Therapy. Efficacy or Lack of Efficacy

Sildenafil in Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia: Friend or Foe?

Irina Branescu, Simona Vladareanu, Sandeep Shetty, Dragos Ovidiu Alexandru, Anay, KulkarniCarol Davila University of Medicine and Pharmacy. St. George’s University Hospital. University of Medicine and Pharmacy of Craiova. Royal Brompton Hospital.Romania and United Kingdom Current Health Sciences JournalCurr Health Sci J 2023; 49: 319-324DOI: 10.12865/CHSJ.49.03.03 AbstractIntroduction: Sildenafil is a phosphodiesterase-5 inhibitor used to treat pulmonary hypertension, although […]

Sildenafil in Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia: Friend or Foe? Read More »

Rescuing lung development through embryonic inhibition of histone acetylation

Giangela Stokes, Zhuowei Li, Nicole Talaba, William Genthe, Maria B. Brix, Betty Pham, Mark D. Weihold, Gracia Sandok, Rebecca Hernan, Julia Wynn, Haiyang Tang, Diana M. Tabima, Allison Rodgers, Timothy A. Hacker, Naomi C. Chesler, Pan Zhang, Rabi Murad, Jason X.-J. Yuan, Yufeng Shen, Wendy K. Chung, David J. McCulleyUniversity of California, San Diego. University

Rescuing lung development through embryonic inhibition of histone acetylation Read More »

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension

Yoo-Jin Kim, Seung Han Shin, Ee-Kyung Kim, Han-Suk KimChung-buk National University Hospital. Seoul National University College of Medicine. Seoul National University Children’s Hospital. Republic of Korea BioMed Central PediatricsBMC Pediatr 2024; 23:DOI: 10.1186/s12887-023-04501-4 AbstractBackground: Pulmonary hypertension (PH) is a life-threatening condition in newborns. We aimed to assess the clinical and echocardiographic responses of term and preterm infants

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension Read More »

Case Report: Stüve-Wiedemann syndrome-a rare cause of persistent pulmonary hypertension of the newborn

Jessica Jin, Paula Rothämel, Johanna Büchel, Birgit Kammer, Theresa Brunet, Joseph Pattathu, Andreas W. Flemmer, Claudia Nussbaum, Sebastian SchroepfDr. von Hauner Children’s Hospital, University Hospital and Ludwig-Maximilians-Universität. University Hospital and Technical University of Munich. Germany Frontiers in PediatricsFront Pediatr 2024;DOI: 10.3389/fped.2023.1329404 AbstractIntroduction: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition characterized by hypoxemia due

Case Report: Stüve-Wiedemann syndrome-a rare cause of persistent pulmonary hypertension of the newborn Read More »

Effective control of refractory pulmonary hypertension with iloprost inhalation in an infant with congenital absence of the right pulmonary artery: a case report

Chu=Yuan Hsiao, Wen-Hsien LuKaohsiung Veterans General Hospital. Fooyin University. National Sun Yat-sen University.Taiwan Cardiology in the YoungCardiol Young 2024;DOI: 10.1017/S104795112300450X AbstractUnilateral absence of the pulmonary artery is a rare congenital cardiovascular anomaly that can lead to pulmonary hypertension and poor outcomes. We report the case of a 1-month-old infant with isolated unilateral absence of the pulmonary

Effective control of refractory pulmonary hypertension with iloprost inhalation in an infant with congenital absence of the right pulmonary artery: a case report Read More »

Vasopressin in newborns with refractory acute pulmonary hypertension

Simon Ouellet, Christine Drolet, Genevéve Morissette, Annie Pellerin, Audrey HébertCHU de Québec, Université Laval. Canada Pediatric ResearchPediatr Res 2024;DOI: 10.1038/s41390-023-02995-3 AbstractBackground: Acute pulmonary hypertension (aPH) in newborns can be life threatening and challenging to manage. In newborns with refractory aPH, there is currently limited therapeutic agents.Methods: Retrospective single-center cohort study in newborns less than one month old who

Vasopressin in newborns with refractory acute pulmonary hypertension Read More »

Never Say Never: The Use of Nitric Oxide in Patients With Obstructed Pulmonary Veins: A Case Report

Victoria Sokoliuk, James A. DiNardo, Morgan L. BrownBoston Children’s Hospital.United States A and A PracticeA A Pract 2019; 12: 205-207DOI: 10.1213/XAA.0000000000000885 AbstractPulmonary vein stenosis (PVS) is a progressive disease with pulmonary hypertension (PH) as a major cause of morbidity and mortality. Traditional management of PH with inhaled nitric oxide (iNO) is typically avoided in PVS patients

Never Say Never: The Use of Nitric Oxide in Patients With Obstructed Pulmonary Veins: A Case Report Read More »

Use of Metformin in Pulmonary Vein Stenosis after TAPVR Repair

Edward C. Kirkpatrick, Michael E. Mitchell, MD, William G. Thilly, Joseph Cava, Aoy Tomita-Mitchell, Elena V. GostjevaChildren’s Hospital of Wisconsin and Medical College of Wisconsin. Massachusetts Institute of Technology. United States Global Pediatric HealthGlob Pediatr Health 2020;DOI: 10.1177/2333794X20958924 AbstractAbstract Not Available CategoryClass II. Pulmonary Hypertension Associated with Pulmonary Vein StenosisMedical Therapy. Efficacy or Lack of EfficacyMedical Therapy. Adverse Effects or Lack of Adverse Effects Age Focus: Pediatric Pulmonary

Use of Metformin in Pulmonary Vein Stenosis after TAPVR Repair Read More »

Bilateral disease and early age at presentation are associated with shorter survival in patients with congenital heart disease and intraluminal pulmonary vein stenosis

Sowmya Balasubramanian, Maliha Rehman, Kimberlee Gauvreau, Kathy J. JenkinsChildren’s Hospital Boston.United States Congenital Heart DiseaseCongenit Heart Dis 2012; 7: 378-386DOI: 10.1111/j.1747-0803.2012.00647.x AbstractPurpose: Pulmonary vein stenosis (PVS) is a progressive disease that is frequently lethal. We have previously identified neoproliferation of myofibroblasts as the mechanism for progressive intraluminal PVS. PVS occurs in association with other congenital heart diseases

Bilateral disease and early age at presentation are associated with shorter survival in patients with congenital heart disease and intraluminal pulmonary vein stenosis Read More »

A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children

Maliha Rehman, Kathy J. Jenkins, Amy L. Juraszek, Jean A. Connor, Kimberlee Gauvreau, Muhammad Muneeb, Laureen M. Sena, Steven D. Colan, Terry Saia, Mark W. KieranChildren’s Hospital, Boston.United States Congenital Heart DiseaseCongenit Heart Dis 2011; 6: 608-623DOI: 10.1111/j.1747-0803.2011.00574.x AbstractObjective: To determine the safety and efficacy of the chemotherapeutic agents vinblastine and methotrexate in the treatment of children

A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children Read More »

Scroll to Top